• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting
Share
Conferences, NEATstik®

ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting

December 5, 2017
-
Posted by Webmaster

ProAxsis’ ProteaseTag® technology will again be featured at the Winter meeting of the British Thoracic Society, which takes place between December 6th-8th at the Queen Elizabeth II Conference Centre, in London. Further details of the abstracts accepted for presentation by the conference review committee are detailed below:

NEATstik® – A Novel Point-of-Care Test for the Measurement of Active Neutrophil Elastase in Patients with Respiratory Disease (Poster no. 116).

Presenting author: Dr Kelly Moffitt (ProAxsis Limited)

Session – Infected lung: from bench to bedside

Thursday 7th December

It is possible to detect active neutrophil elastase in exhaled breath condensate of patients with cystic fibrosis (Poster no. 249).

Presenting author: Dr Claire Edmondson (NHLI Imperial College and Royal Brompton Hospital, London)

Session – Clinical implications of cystic fibrosis

Friday 8th December

Dr David Ribeiro, CEO of ProAxsis, said: “The BTS stated goal is to improve standards of care for people who have respiratory diseases, and the organisation currently has more than 3400 members. Having recently registered a European CE Mark for our rapid neutrophil elastase point-of-care test, NEATstik®, ProAxsis is delighted to be sharing the first data for this exciting new product at the BTS meeting.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com.

December 5, 2017

Related News

Other posts that you should not miss.
NEATstik Airways Test
NEATstik®

ProAxsis reports first NEATstik® sale

February 15, 2018
-
Posted by David Ribeiro

Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of …

Read More
February 15, 2018
Posted by David Ribeiro
Conferences, News

ProAxsis to present at 2016 American Thoracic Society Conference

May 16, 2016
-
Posted by Webmaster

ProAxsis will this week be presenting further data on its ProteaseTag® Active Neutrophil Elastase (NE) Immunoassay, at the American …

Read More
May 16, 2016
Posted by Webmaster
Conferences, News

ProAxsis CEO to present at Biotrinity 2016

April 19, 2016
-
Posted by Webmaster

Dr David Ribeiro, CEO of ProAxsis, will be attending the 10th anniversary Biotrinity conference, taking place in London on …

Read More
April 19, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration
NEXT POST →
ProAxsis provides update on commercialisation progress
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting - ProAxsis